Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Baxter International Inc BAX

Baxter International Inc., through its subsidiaries, provides a portfolio of essential healthcare products. The Company’s Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant and adhesion prevention products. Its Healthcare Systems and Technologies segment includes... see more

NYSE:BAX - Post Discussion

Baxter International Inc > BAX Price Target Alert: $44.00. Issued by Stifel Nicolaus
View:
Post by whytestocks on May 02, 2024 11:30pm

BAX Price Target Alert: $44.00. Issued by Stifel Nicolaus

News; $BAX BAX Price Target Alert: $44.00. Issued by Stifel Nicolaus2024-05-02 15:00:05 ET Rick Wise from Stifel Nicolaus issued a price target of $44.00 for BAX on 2024-05-02 13:10:00. The adjusted price target was set to $44.00. At the time of the announcement, BAX was trading at $36.725. The overall price target consensus is at $84.45...BAX - BAX Price Target Alert: $44.00. Issued by Stifel Nicolaus
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities